Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 49

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 49
---
 herewith.

**Furnished herewith.

ITEM 16. FORM 10-K SUMMARY.

Not applicable.

28

SIGNATURES

Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.

    Dated: March 31, 2025
    DRUGS MADE IN AMERICA ACQUISITION CORP.

    By: 
    /s/ Lynn Stockwell

    Name: 
     Lynn Stockwell

    Title: 
    Chief Executive Officer

Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.

    Name
     
    Position
     
    Date

    /s/ Lynn Stockwell
     
    Chief Executive Officer and Executive Chair
     
    March 31, 2025
  
    Lynn Stockwell
     
    (Principal Executive Officer)

    /s/ Glenn Worman
     
    Chief Financial Officer
     
    March 31, 2025
  
    Glenn Worman
     
    (Principal Financial and Accounting Officer)

    /s/ Catherine Do
     
    Director
     
    March 31, 2025
  
    Catherine Do

    /s/ G. Sridhar Prasad
     
    Director
     
    March 31, 2025
  
    G. Sridhar Prasad

    /s/ Myron W. Shulgan
     
    Director
     
    March 31, 2025
  
    Myron W. Shulgan

29

DRUGS MADE IN AMERICA ACQUISITION CORP.

INDEX TO FINANCIAL STATEMENTS

  Report of Independent Registered Public Accounting Firm (PCAOB ID: 206)   F-2  Financial Statements:      Balance Sheet as of December 31, 2024   F-3  Statement of Operations for the Period from May 23, 2024 (inception) through December 31, 2024   F-4  Statement of Changes in Shareholders’ Deficit for the Period from May 23, 2024 (inception) through December 31, 2024   F-5